2-fluoro-2',3'-dideoxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-fluoro-2',3'-dideoxyadenosine is a synthetic nucleoside analog that inhibits the replication of human immunodeficiency virus (HIV) by acting as a chain terminator during reverse transcription. It is a potent inhibitor of HIV-1 reverse transcriptase and has been shown to have antiviral activity in vitro and in vivo. The compound was initially synthesized in the 1980s and has been extensively studied for its potential as an anti-HIV drug. 2-fluoro-2',3'-dideoxyadenosine has been shown to be effective in treating HIV infection in clinical trials. However, it is not currently approved for use in the United States due to its potential for toxicity. The study of 2-fluoro-2',3'-dideoxyadenosine is important for understanding the mechanisms of viral replication and for developing new antiviral therapies.'

Cross-References

ID Source	ID
PubMed CID	72195
SCHEMBL ID	3054167
MeSH ID	M0156270

Synonyms (12)

Synonym
2-f-dda
[3-(6-amino-2-fluoropurin-9-yl)-2-oxolanyl]methan-1-ol
114849-59-1
[(2s,5r)-5-(6-amino-2-fluoro-purin-9-yl)tetrahydrofuran-2-yl]methanol
2-fluoro-9-(2,3-dideoxy-.beta.-d-glycero-pentofuranosyl)adenine
inchi=1/c10h12fn5o2/c11-10-14-8(12)7-9(15-10)16(4-13-7)6-2-1-5(3-17)18-6/h4-6,17h,1-3h2,(h2,12,14,15)/t5-,6+/m0/s
2-fluoro-2',3'-dideoxyadenosine
2-fdda
adenosine, 2',3'-dideoxy-2-fluoro-
SCHEMBL3054167
DTXSID30150885
[(2s,5r)-5-(6-amino-2-fluoropurin-9-yloxolan-2-yl]methanol

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (18.18)	18.7374
1990's	7 (63.64)	18.2507
2000's	2 (18.18)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.22 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.71 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.22)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
benzoic anhydride [no description available]	2	1	acyclic carboxylic anhydride
dideoxyadenosine Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.	3.78	11	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
coformycin [no description available]	1.97	1	coformycins	EC 3.5.4.4 (adenosine deaminase) inhibitor
fialuridine [no description available]	1.99	1
6-chloropurine riboside [no description available]	2	1
2-chloro-2',3'-dideoxyadenosine [no description available]	1.97	1
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	2.39	2	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.	1.99	1
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.91	4	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
3'-fluoro-2',3'-dideoxyguanosine 3'-fluoro-2',3'-dideoxyguanosine: structure given in first source	1.97	1
2'-fluoro-2',3'-dideoxyinosine 2'-fluoro-2',3'-dideoxyinosine: structure given in first source; RN given refers to compound with unspecified F (fluorine) orientation	2.69	3

Condition	Relationship Strength	Studies
Bare Lymphocyte Syndrome [description not available]	1.98	1
Severe Combined Immunodeficiency Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).	1.98	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.98	1
Cardiac Diseases [description not available]	2.39	2
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.39	2
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	1.98	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.38	2
HIV Coinfection [description not available]	1.99	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	1.99	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1

chemdatabank.com